Myasthenia Gravis Inebilizumab Trial
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
238actual
Sites
104
Countries
Argentina, Belarus, Brazil +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-15 | actual | When the study began enrolling |
| Primary completion | 2024-05-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-07 | estimated | The whole study's end, after follow-up |
| First posted | 2020-08-24 | actual | When this record first appeared on the registry |
| Results posted | 2026-03-10 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myasthenia Gravis
Interventions
- Drug: inebilizumab — also filed as MEDI-551, VIB0551
- Drug: IV Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population
measured Baseline and Week 26
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-09-18 · 2.5 MB · Prot_002.pdf
Statistical Analysis Planposted 2024-08-19 · 872 KB · SAP_001.pdf
Publications
- PMID 42573995 — linked by the registry
- PMID 40202593 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed